U.S. Markets open in 7 hrs 16 mins
  • S&P Futures

    4,391.00
    -12.00 (-0.27%)
     
  • Dow Futures

    34,802.00
    -149.00 (-0.43%)
     
  • Nasdaq Futures

    15,085.75
    -12.25 (-0.08%)
     
  • Russell 2000 Futures

    2,188.90
    -16.20 (-0.73%)
     
  • Crude Oil

    71.27
    -0.80 (-1.11%)
     
  • Gold

    1,808.30
    +6.50 (+0.36%)
     
  • Silver

    25.38
    +0.15 (+0.58%)
     
  • EUR/USD

    1.1783
    +0.0012 (+0.1060%)
     
  • 10-Yr Bond

    1.2860
    0.0000 (0.00%)
     
  • Vix

    17.20
    -0.49 (-2.77%)
     
  • GBP/USD

    1.3747
    -0.0007 (-0.0509%)
     
  • USD/JPY

    110.2920
    -0.2180 (-0.1973%)
     
  • BTC-USD

    38,639.51
    +4,243.13 (+12.34%)
     
  • CMC Crypto 200

    927.16
    +133.43 (+16.81%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,810.62
    +262.62 (+0.95%)
     

G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference. The fireside chat will take place on February 11, 2021 at 2:00 PM ET. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib received Breakthrough Therapy Designation and is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA action date of February 15, 2021. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

Christine Rogers
Associate Director, Corporate Communications
984-365-2819
crogers@g1therapeutics.com